News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Australian Trade Commission (Austrade) Release: Australian Companies Showcase Pharmaceutical Capabilities In Washington D.C.



10/19/2005 5:08:54 PM

Two Australian Companies will be making the annual pilgrimage to the Drug Information Association ("DIA") Annual Meeting in Washington D.C. June 26-30. The Australian businesses attending are companies with a wealth of experience in the clinical pharmaceutical sector in Australia and who are looking to build and strengthen their networks in the United States.

The Queensland Clinical Trials Network Inc. ("QCTN") provides a single point of contact for overseas companies that want to conduct clinical trials in Queensland. When explaining the benefits of doing business in Queensland, Mario Pennisi, CEO of QCTN said "Queensland is extremely competitive in conducting clinical trials when compared to the U.S., Canada and Europe. Additionally, the counter-seasonality with these regions means trial sites can be initiated up to six months earlier".

Also involved in the DIA meeting is Clinical Network Services. Clinical Network Services (CNS) is a privately-owned Australian Contract Research Organization (CRO). Since its foundation in 1998, they continue to be the only Queensland head-quartered CRO offering Clinical Research Management services. Based in suburban Brisbane, they are well-situated to take advantage of a local population of 3 million people and some of the most respected hospitals and research services in Australia.

"Australia has become increasingly competitive and effective in delivering clinical trial services for the development of drugs for European and US companies. As a "new world" much like the US, it offers heterogeneous racial and ethnic populations, experienced clinicians and scientists and well-regulated protocols for these services. We're excited to showcase proven Australian companies to the US marketplace," said Helen Karuso, Business Development Manager with the Australian Trade Commission. The Australian Government encourages members of the United States Pharmaceutical community to meet with these companies while at DIA. To facilitate meetings please contact the Australian Trade Commission representatives in the United States listed below.

For more information contact:

Alexander Jeglic Austrade, Embassy of AustraliaWashington DC Tel: (202) 797 3166Email: Alex.jeglic@Austrade.gov.au

Helen KarusoAustrade, Embassy of Australia Tel : 202 797 3472Email : Helen.Karuso@austrade.gov.au Web: http://www.austrade.gov.au


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES